Drug Profile
Fibroblast growth factor receptor antagonist - Eli Lilly and Company
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer in USA
- 06 Jul 2011 Phase-I clinical trials in Cancer in USA (unspecified route)
- 21 Apr 2010 Preclinical trials in Cancer in USA (unspecified route)